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Purpose: To investigate the effect of intravitreal pegaptanib, bevacizumab, and ranibizumab 
on blood-vessel formation during cutaneous wound healing in a rabbit model and to compare 
this effect to placebo controls.
Methods: Forty New Zealand albino rabbits underwent full thickness cutaneous wounds 
using 6-mm dermatologic punch biopsies. The rabbits were assigned to four groups of ten, 
each receiving intravitreal injections of pegaptanib, bevacizumab, ranibizumab, or no injection 
(untreated controls). Five rabbits from each group underwent wound harvesting on day 7 and five 
from each group on day 14. The skin samples were stained with hematoxylin and eosin (HE), 
Masson’s trichrome (MT), and CD34 for vascular endothelial cells. Semiquantitative evaluation 
of HE- and MT-stained slides was performed by one pathologist. Quantitative assessment of 
mean neovascularization (MNV) scores was obtained from five contiguous biopsy margin 
400× fields of CD34-stained sections by four independent observers.
Results: Week 1 MNV scores in CD-34 stained sections were: untreated controls: 11.51 ± 4.36; 
bevacizumab: 7.41 ± 2.82 (P = 0.013); ranibizumab: 8.71 ± 4.08 (P = 0.071); and pegaptanib: 
10.15 ± 5.59 (P = 0.378). Week 2 MNV data were: untreated controls: 6.14 ± 2.25; bevacizumab: 
7.25 ± 2.75 (P = 0.471); ranibizumab: 4.53 ± 3.12 (P = 0.297); and, pegaptanib: 6.35 ± 3.09 
(P = 0.892). Interobserver variability using intraclass correlation coefficient was 0.961.
Conclusions: At week 1, all three anti-VEGF agents had suppressed MNV scores compared to 
controls. Although not statistically significant, there was an inhibitory trend, particularly with 
bevacizumab and ranibizumab. These effects were diminished at 2 weeks, reflecting a transition 
between the proliferative and remodeling phases of wound healing.
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Introduction
The use of agents that suppress vascular endothelial growth factor (VEGF) is 
currently the standard of care for the treatment of the wet form of age-related macular 
degeneration. The three most commonly used agents are ranibizumab, bevacizumab, and 
pegaptanib. Bevacizumab and ranibizumab target all VEGF isoforms while pegaptanib 
specifically targets the 165 isoform of VEGF. Bevacizumab and ranibizumab are 
currently the mainstays of treatment of the exudative form of macular degeneration 
while pegaptanib is often used as maintenance. In 2010, ranibizumab was approved by 
the US Food and Drug Administration for the treatment of macular edema secondary 
to central and branch retinal vein occlusion. Both ranibizumab and bevacizumab are 
widely used on an off-label basis for the treatment of diabetic macular edema in the 
US. It is estimated that there are 1.75 million patients in the US who have the wet 
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form of macular degeneration with approximately 200,000 
new cases of wet age-related macular degeneration diagnosed 
annually.1 In addition, there are expected to be 16.4 million 
patients with central retinal vein occlusion and branch retinal 
vein occlusion worldwide2 with 35,000 new cases of central 
retinal vein occlusion diagnosed annually in the US alone.3 
While approximately 900,000 diabetic patients have vision 
threatening retinopathy, future projections suggest that 
these numbers will increase with both the aging of the US 
population as well as the increasing prevalence of diabetes 
mellitus.4 Typically, patients in these treatment groups 
require a mean of 3–7 intravitreal injections of an anti-VEGF 
agent annually per affected eye.
The side effects of systemic use of bevacizumab have been 
closely examined and, in addition to delayed wound healing, 
include hypertension,5–8 proteinuria,5,9 thromboembolic 
events,5,10 hematuria,5 epistaxis,5 gastrointestinal hemorrhage,11 
hemoptysis,12 pulmonary hemorrhage,12 gastrointestinal 
perforation,13  skin rash,14 and pain.19 The effects on peripheral 
wound healing have been particularly well-documented since 
these patients often undergo tumor chemoreduction prior to 
surgical resection or undergo venous access port placement. 
Associated wound-healing complications with systemic 
bevacizumab include infusion port wound dehiscence, 
ecchymoses, incisional hernias, surgical site bleeding, 
and infection.15–19 These complications are especially seen 
in patients greater than 60 years of age.19 Although there 
is no clear consensus, reports from the literature for the 
perioperative use of systemic bevacizumab recommend 
that it be discontinued 6–8 weeks prior to elective surgery 
and started or restarted 4 weeks after surgery.15–22 Despite 
the deleterious effects of wound healing that have been 
reported with the use of systemic bevacizumab, this effect 
has not been specifically examined in the ophthalmology 
literature following intravitreally administered anti-VEGF 
agents. The results from the Comparison of Age-Related 
Macular Degeneration Treatments Trials did not specifically 
examine wound healing complications following intravitreal 
ranibizumab or bevacizumab injection.23 Perhaps because 
the doses of intravitreal bevacizumab are approximately 
150 to 500 times less than the standard intravenous dose, 
it is generally presumed that these agents exert little effect 
systemically. However, it is imperative to study any possible 
effects on cutaneous wound healing as a result of intravitreal 
anti-VEGF therapy. Patients who receive intravitreal anti-
VEGF therapy are at particular risk to undergo a surgical 
procedure during the course of their treatment. According to 
the National Hospital Discharge Survey, in 2005 there were 
8.86 million surgical procedures performed in the US in 
patients over the age of 65.24 Currently, it is unclear whether 
or not intravitreal anti-VEGF therapy is safe in the presence 
of an open wound or during the perioperative period.
Previous reports of deleterious cutaneous wound healing 
by systemic bevacizumab have led us to examine whether 
or not intravitreal anti-VEGF therapy may cause a similar 
effect. In this study, we specifically examined the histo-
pathologic effects of intravitreally administered ranibizumab, 
bevacizumab, and pegaptanib on angiogenesis of the skin 
during peripheral cutaneous wound healing in a normal 
rabbit model.
Methods
Forty male New Zealand albino rabbits (Myrtle’s Rabbitry, 
Thompsons Station, TN) weighing 3.8–3.9 kg were used for 
this study. All treatments were conducted in agreement with 
the ARVO Statement for the Use of Animals in Ophthalmic and 
Vision Research. All experimental protocols were approved, 
and the procedures followed were in accordance with the 
ethical standards of the Institutional Animal Care and 
Use Committee at The Ohio State University. Before the 
procedure, each rabbit was given 0.3 mg/kg of meloxicam 
PO. Anesthesia was induced with 10 mg/mL acepromazine 
subcutaneously and maintained with isoflurane. The rabbit’s 
dorsal skin was shaved with electric clippers and cleansed 
with 10% povidone-iodine and 70% alcohol swabs before 
manipulation. A standard 6-mm dermatologic punch biopsy 
(Sklar Tru Punch, Sklar Instruments, West Chester, PA) with 
retention of the skin core was then created on the exposed 
skin, 3 cm lateral to the cervicothoracic vertebral column 
over the scapula.
The rabbits were assigned into one of four treatment 
groups (n = 10/treatment group): ranibizumab, bevacizumab, 
pegaptanib, and no treatment. An intravitreal injection vol-
ume of 0.05 mL with either 0.5 mg/0.05 mL ranibizumab, 
1.25 mg/0.05 mL bevacizumab, or 0.3 mg/0.1 mL pegap-
tanib was placed 1 mm posterior to the limbus of the left 
eye. Untreated control rabbits did not receive intravitreal 
injections.
Skin including the biopsy site with surrounding normal 
skin, was excised from rabbits under anesthesia as described 
above 1 week and 2 weeks post-treatment (n = 5/treatment 
group/time point). The anesthetized rabbits were then 
euthanized by intravenous injection of 3 mL of saturated 
potassium chloride.
Skin samples were immediately placed into 10% neutral-
buffered formalin, switched to 70% ethanol after 24–48 hours, 
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routinely processed, embedded in paraffin wax, and sec-
tioned at 5 µm. Serial sections were routinely stained with 
hematoxylin-eosin (HE) as well as Masson’s trichrome (MT) 
for collagen. Wound healing in HE- and MT-stained slides 
was semiquantitatively evaluated by an experienced patholo-
gist (KL) blinded to experimental groups, with an Olympus 
BX45 light microscope with attached DP25 digital camera 
(B&B Microscopes Limited, Pittsburgh, PA) according to 
the histologic scoring system by Abramov et al.25 In brief, 
acute and chronic inflammation, amount and maturation of 
granulation tissue, collagen deposition, re-epithelialization, 
and neovascularization were assessed independently and 
assigned a score of 0–3. According to this scheme, a score 
of 0 indicates none or no cells; 1, scant; 2, moderate; and 3, 
abundant. For re-epithelialization a score of 0 represents none; 
1, partial; 2, complete but immature or thin; and 3, complete. 
For neovascularization a score of 0 indicates no vessels/high 
power field; 1, up to 5 vessels/high power field; 2, 6–10 ves-
sels/high power field; and 3, more than 10 vessels/high power 
field. Acute inflammation was defined by the presence of 
neutrophils, while chronic inflammation was characterized 
by lymphoplasmacytic and monocytic infiltrates.
Serial paraffin sections on poly-L-lysine slides were also 
immunohistochemically stained for CD34 to identify vascular 
endothelial cells using a Dako Universal Training Center 
autostainer (Carpinteria, CA). Sections were deparaffinized 
in xylene and rehydrated prior to pretreatment with Target 
Retrieval Solution (Dako) in a decloaking chamber. 
Endogenous peroxidase was inhibited by 3% hydrogen 
peroxide, followed by serum-free protein block, each for 
10 minutes. Sections were incubated at room temperature 
first with anti-CD34 (C-18) antibody (1:150, catalog #7045; 
Santa Cruz Biotechnology, Inc, Santa Cruz, CA), and 
then with biotinylated anti-goat IgG (Vector Laboratories, 
Burlingame, CA), each for 30 minutes. Specific binding 
was amplified with RTU Vectastain Elite ABC Kit (Vector 
Laboratories). Chromogen reaction was developed with 
3-3′diaminobenzidine solution (Dako) for 5 minutes, and 
nuclei were counterstained with hematoxylin.
Five contiguous 400× fields at biopsy site margins of 
CD34-stained sections were photographed using a six-
headed Olympus BX51 light microscope with attached Altra 
20   digital camera and MicroSuite software linked to a 42″ 
Panasonic plasma television (B&B Microscopes Limited). 
By convention, the wound margin on the left aspect of the 
microscope slide was chosen. The photomicrographs were 
then randomly presented to four independent   observers 
(JC, RR, CP, and MW) and a recorder, all blinded to 
experimental groups, and CD34-stained endothelial cell 
clusters were recorded. To reduce interobserver bias, the 
photomicrographs were presented in random order and each 
observer was blinded to the counts of the other observers. 
Observer means for each photomicrograph and mean 
neovascularization (MNV) scores representing all scores for 
the five photomicrographs evaluated were calculated.
Statistical analysis of HE and MT semiquantitative scores 
was performed using Fisher’s exact test. The comparisons 
were between placebo and other agents at 7 days and 14 days. 
Standard deviations were shown with all means. CD34 
endothelial cell cluster counts were first averaged across 
slides for each rater within each subject to avoid systematic 
error, and then the averaged values were analyzed using a lin-
ear mixed-effects model to account for the correlation of the 
observations from the same animal. In this model, the fixed 
effects are time, treatment, and time by treatment interaction 
where treatment is the three therapeutic agents and untreated 
controls, and time is the two time points when the measure-
ments were made. The variance of subject and the rater by 
subject variation were estimated using a random statement. 
In the model, the variance component correlation structure 
was used for both as the covariance structure. In addition, 
the same model was used to make comparisons between the 
three therapeutic agents. Holm’s procedure was used to adjust 
for multiple comparisons between the four groups at each 
of the two time points. After Holm’s adjustment, statistical 
significance was considered to be present with P , 0.0063 
(0.05/8) for the most significant ones, then with P , 0.0071 
(0.05/7) for the second significant ones, and so on.
Intraclass correlation coefficient was used to investi-
gate inter-rater agreement by relating the between subject 
variabilty to the total variability in our linear mixed model.26 
All analyses were performed using SAS/STAT software 
(version 9.2; SAS Institute Inc, Cary, NC) using the   Windows 
XP system.
Results
All of the rabbits that underwent intravitreal injection had 
clearly evident cutaneous wounds at the time of harvest. 
None of the wounds exhibited signs of infection at the time 
of harvesting.
Seven parameters of wound healing were semiquanti-
tatively assessed in HE- and MT-stained skin sections, and 
none were found to be statistically significant either at 1 or 
2 weeks (Table 1). While semiquantitative neovascularization 
scores for treated animals at 1 week were the same or slightly 
reduced compared to untreated controls, small-diameter 
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neovessels were difficult to differentiate from activated 
fibroblasts in HE- and MT-stained sections. Therefore, CD34 
immunohistochemical staining was performed for further 
assessment of neovascularization.
Mean neovascularization scores were calculated in wound 
margins from CD34-stained rabbit skin sections at 1 and 2 
weeks following wounding and treatment with three   different 
anti-VEGF agents (Figure 1). Wound margin borders in skin 
sections from 39/40 rabbits were clearly visible by light 
microscopy and were scored. The margins of one specimen 
(bevacizumab, 1 week) were indeterminate by all four 
reviewers despite sectioning deeper in the paraffin block and 
processing of additional skin samples, and as a result were 
excluded from scoring.
Table 1 Semiquantitatively scored histologic parameters of cutaneous wound healing in normal rabbits treated with intravitreal   
anti-VEGF agents
Treatment AI CI GA GM CD RE NV
7 days
Untreated 2.2 ± 0.84 1.6 ± 0.55 2.2 ± 0.84 1.8 ± 1.30 1.2 ± 0.45 1.4 ± 1.52 1.6 ± 0.89
Bevacizumab 1.2 ± 0.45 1.2 ± 0.45 1.6 ± 0.55 2.4 ± 0.55 1.6 ± 0.55 2.2 ± 0.89 1.6 ± 0.55
P = 0.292 P = 0.524 P = 0.524 P = 0.714 P = 0.524 P = 0.683 P = 0.524
Ranibizumab 1.6 ± 0.55 1.6 ± 0.55 2.2 ± 0.45 2.0 ± 0.00 1.8 ± 0.45 2.6 ± 0.89 1.40 ± 55
P = 0.524 P = 1.000 P = 0.524 P = 0.048 P = 0.206 P = 0.683 P = 1.000
Pegaptanib 1.6 ± 0.55 1.2 ± 0.45 1.8 ± 0.45 2.0 ± 0.71 1.6 ± 0.55 2.2 ± 1.10 1.2 ± 0.45
P = 0.524 P = 0.524 P = 0.683 P = 0.714 P = 0.524 P = 0.524 P = 1.000
14 days
Untreated 1.0 ± 0.0 1.2 ± 0.45 1.8 ± 0.45 2.4 ± 0.55 2.2 ± 0.45 3.0 ± 0.00 1.6 ± 0.55
Bevacizumab 1.2 ± 0.40 1.4 ± 0.55 1.8 ± 0.45 3.0 ± 0.00 2.0 ± 0.00 3.0 ± 0.00 1.4 ± 0.55
P = 1.000 P = 1.000 P = 1.000 P = 0.167 P = 1.000 P = 1.000 P = 1.000
Ranibizumab 1.4 ± 0.55 1.4 ± 0.55 2.0 ± 0.00 2.2 ± 0.45 1.8 ± 0.45 3.0 ± 0.00 1.60 ± 0.55
P = 0.444 P = 1.000 P = 1.000 P = 1.000 P = 1.000 P = 1.000 P = 1.000
Pegaptanib 1.8 ± 0.45 1.4 ± 0.55 2.0 ± 0.71 1.8 ± 0.84 1.8 ± 0.45 2.6 ± 0.89 2.2 ± 0.45
P = 0.048 P = 1.000 P = 1.000 P = 0.524 P = 1.000 P = 1.000 P = 0.444
Notes: n = 5/group; mean ± standard deviation.
Abbreviations: AI, acute inflammation; CI, chronic inflammation; GA, amount of granulation tissue; GM, maturation of granulation tissue; CD, collagen deposition; 
RE, re-epithelialization; nV, neovascularization.
(CD34-20X)
(CD34-20X) (CD34-400X)
(CD34-400X)
A
CD
B
Figure  1  Representative  CD34  histological  figures  of  cutaneous  wounds  1  week  after  wounding.  At  20×  wound  margins  are  demonstrated  (arrows)  (A  and  C).   
At 400× , note increased endothelial cell counts in the placebo (about 11) (B) versus ranibizumab (about 6) (D).
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At 1 week post-treatment, none of the treatment groups 
was found to inhibit, at a statistically significant level, the 
number of vessels compared to the placebo group. However, 
at this time point all of the treatment groups had lower MNV 
scores than untreated controls (shown as mean with standard 
deviation and 95% confidence interval [CI]). Compared 
to untreated controls (11.51 ± 4.36, 95% CI: 9.25, 13.77), 
bevacizumab (7.41 ± 2.82, 95% CI: 5.79, 9.04, P = 0.013) 
inhibited neovascularization in cutaneous wound margins. 
The effect was less significant for ranibizumab (8.71 ± 4.08, 
95% CI: 7.00, 10.42, P = 0.071); and much diminished for 
pegaptanib (10.15 ± 5.59, 95% CI: 8.16; 12.14, P = 0.378). 
At week 2, the effect was greatly diminished as none of the 
agents was found to have a statistically significant inhibitory 
effect on neovascularization. Ranibizumab (4.53 ± 3.12, 95% 
CI: 3.64, 5.42, P = 0.297) had a lower mean MNV score 
compared to untreated controls (6.14 ± 2.25, 95% CI: 4.94, 
7.34) (Figure 2). The mean MNV scores were higher than 
placebo for both bevacizumab (7.25 ± 2.75, 95% CI: 5.83, 
8.67, P = 0.471) and pegaptanib (6.35 ± 3.09, 95% CI: 
5.11, 7.59, P = 0.892). Compared to day 7, there was a 
statistically significant reduction in neovessel formation at 
day 14 (P , 0.0001) averaged across all treatment groups. 
Evaluation of interobserver variability as assessed by the 
intraclass correlation coefficient was 0.961, indicating a high 
agreement on the reading of the slides among raters.
Discussion
In our study, all three intravitreal anti-VEGF agents 
were found to suppress neovascularization by qualitative 
  assessment of MNV by CD34 immunostaining of cutaneous 
wound margins evaluated 1 week following treatment 
compared to untreated controls. Although these were not 
found to be statistically significant, there was an inhibitory 
trend, particularly with bevacizumab and ranibizumab. 
At 2 weeks following treatment, this effect was suppressed 
in all three agents, presumably because the wounds had 
transitioned to the remodeling phase of healing during which 
there are decreased numbers of blood vessels.27 Interestingly, 
the bevacizumab and pegaptanib groups had higher MNV 
scores than the untreated group at the latter time point. 
Although it is not clear why this effect occurred, since the 
effect of anti-VEGF therapy at the maturation phase of wound 
healing is uncertain, this finding is not likely to be clinically 
significant because of the suppressed scores in all groups. 
Furthermore, these differences at week 2 between treatment 
arms and placebo were more greatly reduced than at week 
1. Semiquantitative assessment of HE- and MT-stained 
slides did not reveal any consistent or statistically significant 
differences in parameters of wound healing. This may be 
because of the narrow scoring system applied (0 to 3), the 
small sample size per experimental group, and retention of 
the core at the time of punch biopsy.
This work is the first to demonstrate that intravitreally 
placed anti-VEGF agents can exert an effect on cutaneous 
wound healing by exhibiting a reduction in vessel numbers 
during the proliferative phase. During wound healing, 
angiogenesis occurs in the proliferation phase typically 
between days 4 and 14.28 The new vasculature allows for 
cellular migration and proliferation and for the deposition of 
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Figure 2 Mean neovascularization (MnV) scores with standard deviations and P-values in wound margins from CD34-stained rabbit skin sections at 1 and 2 weeks following 
wounding and intravitreal treatment with three different anti-VEGF agents. Each mean reflects endothelial cell cluster counts in 25, 400× field photomicrographs/treatment 
group/time point. Neovascularization was significantly inhibited by all agents, most notably bevacizumab, at 1 week only. Note that at week 2 the differences between placebo 
and all three treatment arms are reduced.
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a fibrin-rich matrix that forms the granulation tissue needed 
to close the wound. Disturbance of angiogenesis during the 
proliferation phase affects the restoration of dermal integrity 
that is vital for re-epithelialization of a cutaneous wound.29 
The proliferative phase is then followed by the maturation 
phase during which time there is a decrease in the number of 
blood vessels in the wound.26 It has been previously reported 
that the integrity of the wound is affected if the proliferation 
phase is suppressed.30 This is a likely mechanism by which 
systemic bevacizumab exerts its inhibitory effect on cuta-
neous wound healing that has been previously described in 
clinical studies.16–22 Further studies are warranted to evalu-
ate whether or not intravitreal anti-VEGF therapy affects 
integrity and blood flow at the wound margins as well as 
final tensile wound strength.
There have been several clinical studies that have 
examined the effect of systemic bevacizumab on wound 
healing. In a retrospective study, Scappaticci et al18 compared 
wound-healing complications in patients that underwent 
surgery for metastatic colon cancer during treatment with and 
without intravenous bevacizumab. Ten of 75 bevacizumab-
treated patients (13%) compared to 1 of 29 control patients 
(3.4%) had wound healing complications including 
bowel perforation, abdominal fistula, bowel dehiscence, 
hemothorax and thoracotomy wound dehiscence. While 
not statistically significant, these findings were found to be 
clinically important and the recommendation was to monitor 
these patients closely after surgery.18 In another retrospective 
study by Zawacki et al16, 6/195 (3.1%) bevacizumab-treated 
patients compared to 0/915 controls developed wound 
dehiscence. Furthermore, 5/49 patients (10.2%) receiving 
bevacizumab within 7 days of port placement developed 
wound dehiscence. These findings were statistically 
significant and the authors concluded that wound dehiscence 
after port placement was related to timing of bevacizumab 
therapy. They recommended delaying bevacizumab therapy 
for at least 28 days after major surgery.16 Two large treatment 
studies, Bevacizumab Regiments: Investigation of Treatment 
Effects and Safety (BRiTE)22 and Bevacizumab Expanded 
Access Trial (BEAT),19 found increased risks of wound 
healing complications when   surgery was performed within 
60 days after discontinuation of   bevacizumab compared to 
a longer interval.
The systemic effects of intravitreal anti-VEGF agents 
have been investigated in several reports. Both bevacizumab 
and ranibizumab have been associated with low rates of 
hypertension and arterial thromboembolic events including 
cerebrovascular accident, myocardial infarction, transient 
ischemic attack, and angina pectoris.31–33 The safety and rates 
of   serious adverse events of these two intravitreal agents is 
being further evaluated in the Comparison of Age-Related 
Macular   Degeneration Treatments Trials Study.23 The reported 
incidences from these studies are small and they do not have 
enough statistical power to detect low rates of these events.34 
These adverse events have not been associated with the use 
of pegaptanib, although patients with a history of   myocardial 
infarction within 6 months and stroke within 1 year before 
the study were excluded from the VEGF Inhibition Study in 
Ocular Neovascularization (VISION) trial.35 As a result, the 
effects on wound healing have not been specifically addressed. 
In clinical practice,   ophthalmologists often do not specifically 
ask for a patient’s recent or   upcoming surgical history, or 
examine for the presence of any   cutaneous wounds at the 
time of intravitreal injection.
It is often assumed that intravitreal agents are minimally 
accessible to the peripheral circulation. Firstly, anti-VEGF 
agents are used in much lower quantities for treating ocular 
disorders than as intravenous chemotherapeutic agents. 
Secondly, VEGF is only one of several factors involved in 
angiogenesis during wound healing.36–38 Thirdly, the contents 
of the vitreous cavity are largely kept separate from the 
systemic circulation by the ocular–blood barrier. Finally, 
currently used anti-VEGF agents are antibodies, antibody 
fragments, and RNA aptamers which are large molecules 
by pharmacologic standards and less likely to pass through 
the ocular–blood barrier.
Data on the pharmacokinetics of anti-VEGF agents 
after intravitreal injection in humans are scarce. However, 
there have been several studies in animal models that have 
demonstrated measurable amounts of these agents in the 
peripheral circulation following intravitreal injection. 
Bilateral intravitreal injections of 0.5 mg of ranibizumab 
in a nonhuman primate model showed peak serum levels of 
150 ng/mL and sustained levels to greater than 10 ng/mL 
at 1 week.39 After intravitreal injection of bevacizumab in 
a cynomolgus macaque model, maximal serum levels of 
1430 ± 186 ng/mL were achieved 1 week after injection.40 
Due to even smaller serum volumes, serum levels have been 
found to be much higher in a rabbit model (3.3 µg/mL) 8 days 
after intravitreal injection of 1.25 mg of bevacizumab.41 With 
regard to pegaptanib, one study demonstrated that after a 
single 3.0 mg intravitreal injection, mean plasma levels 
were 80 ng/mL.42 Despite the inherent problems posed by 
relating human data to findings in non-neovascular animal 
models, it is important to realize that some amounts of 
these agents escape from the vitreous cavity into the serum. 
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Furthermore, it would be expected that in a choroidal neo-
vascular model there would be increased levels of the agents 
exiting the eye due to breakdown of the blood–eye barrier. In 
addition, the effect would likely be greater in humans due to 
the greater affinity of these agents to human VEGF.
Although the peripheral levels of anti-VEGF agents 
  mentioned above may seem nominal, they become impressive 
when compared to normal serum levels of VEGF. VEGF   levels 
in the adult human as well as the rabbit model are usually less 
than 100 pg/mL, at least two orders of magnitude less than drug 
concentrations seen in the aforementioned studies. In a study by 
Grad et al, VEGF levels in multiple trauma patients were 742 ± 
152 pg/mL at their highest as compared to 82.2 ± 10.8 pg/mL 
(mean ± SEM) in healthy controls.43 In another study, normal 
serum and plasma levels were less than 100 pg/mL with little 
effect by age.44 Normal VEGF serum levels in rabbits cor-
relate with those of humans, have been found to be less than 
62 pg/mL, and can increase up to 1000 pg/mL under severely 
hypoxic conditions.45 This amount of escape of anti-VEGF 
agents may be enough to suppress VEGF systemically.32
There are some inherent limitations to this study. First, 
the use of a rabbit model has several inherent constraints. 
The serum compartment is significantly smaller than that 
of humans, while the vitreous volume in rabbits is approxi-
mately one-third that of humans (4.5 mL vs 1.5 mL), thereby 
increasing systemic exposure of a humanly dosed intravitreal 
anti-VEGF agent. In addition, although rabbit VEGF has 
been found to bind to bevacizumab,46 rabbit VEGF is 94% 
homologous with human counterparts of VEGF 121, 165, 
and 189 isoforms.47 An additional limitation is the exclusion 
of one skin sample from the 1 week bevacizumab group due 
to the lack of identifiable wound margins. It is uncertain 
how this would affect statistical significance given that the 
other two anti-VEGF treatment groups had similar results. 
Furthermore, it would be unlikely for one specimen in the 
bevacizumab group to significantly alter the 1-week results of 
our study. The controls in our study did not undergo intravit-
real injection with saline or another inert vehicle. Intravitreal 
injection is minimally invasive and would not be expected to 
produce any significant elevation of serum VEGF levels.45 If 
such an elevation occurred, it would be expected to further 
increase the neovascularization in controls. Retention of the 
core at the time of the punch biopsy minimized the wound 
defect which had to heal. However, removal of the core, 
resulting in a larger defect to re-epithelialize and fuse would 
closely mimic the wounding scenario in patients and likely 
result in even greater anti-angiogenic effects. Lastly, we were, 
unfortunately, not able to directly measure ranibizumab and 
bevacizumab in the blood because the methodology was not 
available at our institution or any of our referral labs.
Although it may be presumptuous to make clinical 
recommendations based on the results of this preliminary 
study, it is important to emphasize that several reports have 
demonstrated the deleterious effects on wound healing by 
systemic bevacizumab.16–22 The amounts of these agents that 
escape from the vitreous into the serum have been found 
to be high enough to suppress peripheral VEGF.38–42 As a 
result, we encourage clinicians to be aware of the potential 
for delayed wound healing, to be observant of their patients’ 
recent surgical history and/or the presence of any open 
wounds. Based on the inhibitory trend in our study during the 
proliferative stage of wound healing on day 7, we recommend 
refraining from the use of intravitreal bevacizumab and 
ranibizumab in the presence of open wounds and 4–6 weeks 
before and 4 weeks after surgery. The use of pegaptanib 
or alternative forms of maintenance therapy such as 
photodynamic therapy could be recommended during this 
time interval. Finally, we suggest that patients undergoing eye 
surgery have any ocular wounds (ie, sclerotomy site from any 
gauge vitreoretinal procedures or cataract incisions) sutured 
when receiving intraoperative intravitreal bevacizumab. It is 
presumed that preoperatively administered anti-VEGF agents 
are washed out during the vitrectomy.
In summary, all three intravitreal anti-VEGF were found to 
inhibit neovascularization at cutaneous wound margins 1 week 
following treatment when compared to untreated   controls. 
Although not statistically significant, there were definite 
inhibitory trends seen with bevacizumab and ranibizumab. 
Because of the large numbers of patients that may be affected 
by delayed wound closure after such treatments, continued 
investigation of the systemic effects of intravitreal anti-VEGF 
therapy with a larger number of subjects is warranted.
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